News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
337,487 Results
Type
Article (31154)
Company Profile (132)
Press Release (306201)
Multimedia
Podcasts (36)
Webinars (7)
Section
Business (85052)
Career Advice (579)
Deals (12566)
Drug Delivery (53)
Drug Development (54194)
Employer Resources (51)
FDA (8584)
Job Trends (7808)
News (159655)
Policy (13861)
Tag
Academia (1989)
Academic (1)
Accelerated approval (4)
Adcomms (18)
Allergies (25)
Alliances (25237)
ALS (48)
Alzheimer's disease (896)
Antibody-drug conjugate (ADC) (147)
Approvals (8573)
Artificial intelligence (156)
Autoimmune disease (12)
Automation (6)
Bankruptcy (116)
Best Places to Work (6592)
BIOSECURE Act (4)
Biosimilars (56)
Biotechnology (106)
Bladder cancer (84)
Brain cancer (28)
Breast cancer (315)
Cancer (2441)
Cardiovascular disease (89)
Career advice (472)
Career pathing (8)
CAR-T (146)
Cell therapy (345)
Cervical cancer (22)
Clinical research (44100)
Collaboration (533)
Company closure (2)
Compensation (186)
Complete response letters (10)
COVID-19 (1421)
CRISPR (25)
C-suite (112)
Cystic fibrosis (41)
Data (1551)
Decentralized trials (1)
Denatured (8)
Depression (13)
Diabetes (111)
Diagnostics (4113)
Digital health (8)
Diversity (6)
Diversity, equity & inclusion (15)
Drug discovery (73)
Drug pricing (64)
Drug shortages (5)
Duchenne muscular dystrophy (17)
Earnings (27957)
Editorial (20)
Employer branding (7)
Employer resources (45)
Events (53288)
Executive appointments (344)
FDA (9347)
Friedreich's ataxia (2)
Frontotemporal dementia (4)
Funding (405)
Gene editing (48)
Generative AI (9)
Gene therapy (147)
GLP-1 (292)
Government (2350)
Grass and pollen (2)
Guidances (64)
Healthcare (11551)
Huntington's disease (6)
IgA nephropathy (8)
Immunology and inflammation (63)
Indications (17)
Infectious disease (1504)
Inflammatory bowel disease (74)
Inflation Reduction Act (7)
Influenza (28)
Intellectual property (44)
Interviews (82)
IPO (6151)
IRA (29)
Job creations (1492)
Job search strategy (435)
Kidney cancer (11)
Labor market (13)
Layoffs (228)
Leadership (3)
Legal (2189)
Liver cancer (81)
Lung cancer (348)
Lymphoma (154)
Machine learning (3)
Management (17)
Manufacturing (137)
MASH (39)
Medical device (5365)
Medtech (5368)
Mergers & acquisitions (6644)
Metabolic disorders (275)
Multiple sclerosis (42)
NASH (4)
Neurodegenerative disease (38)
Neuropsychiatric disorders (13)
Neuroscience (1133)
NextGen: Class of 2025 (3657)
Non-profit (3146)
Now hiring (8)
Obesity (121)
Opinion (96)
Ovarian cancer (83)
Pain (42)
Pancreatic cancer (90)
Parkinson's disease (58)
Partnered (10)
Patents (107)
Patient recruitment (90)
Peanut (15)
People (25795)
Pharmaceutical (29)
Pharmacy benefit managers (7)
Phase I (14702)
Phase II (19434)
Phase III (13963)
Pipeline (778)
Policy (86)
Postmarket research (1639)
Preclinical (6011)
Press Release (33)
Prostate cancer (114)
Psychedelics (12)
Radiopharmaceuticals (239)
Rare diseases (190)
Real estate (3311)
Recruiting (16)
Regulatory (10629)
Reports (18)
Research institute (1827)
Resumes & cover letters (82)
Rett syndrome (1)
RNA editing (2)
RSV (29)
Schizophrenia (33)
Series A (58)
Series B (33)
Service/supplier (2)
Sickle cell disease (37)
Special edition (5)
Spinal muscular atrophy (47)
Sponsored (12)
Startups (1694)
State (1)
Stomach cancer (16)
Supply chain (21)
Tariffs (19)
The Weekly (27)
Vaccines (465)
Venture capitalists (16)
Weight loss (78)
Women's health (20)
Worklife (4)
Date
Last 7 days (450)
Last 30 days (1582)
Last 365 days (17263)
2025 (6093)
2024 (18731)
2023 (21260)
2022 (28557)
2021 (29727)
2020 (27704)
2019 (24290)
2018 (18134)
2017 (16339)
2016 (16019)
2015 (18355)
2014 (13743)
2013 (11205)
2012 (11705)
2011 (12119)
2010 (10996)
Location
Africa (289)
Alabama (18)
Alaska (4)
Arizona (96)
Arkansas (6)
Asia (21652)
Australia (3528)
California (3321)
Canada (880)
China (384)
Colorado (163)
Connecticut (143)
Delaware (103)
Europe (42928)
Florida (452)
Georgia (107)
Idaho (25)
Illinois (318)
India (13)
Indiana (165)
Iowa (5)
Japan (95)
Kansas (39)
Kentucky (19)
Louisiana (9)
Maine (9)
Maryland (506)
Massachusetts (2365)
Michigan (88)
Minnesota (191)
Mississippi (1)
Missouri (44)
Montana (14)
Nebraska (12)
Nevada (24)
New Hampshire (44)
New Jersey (1046)
New Mexico (14)
New York (1098)
North Carolina (402)
North Dakota (3)
Northern California (1548)
Ohio (111)
Oklahoma (8)
Oregon (16)
Pennsylvania (669)
Puerto Rico (6)
Rhode Island (14)
South America (410)
South Carolina (10)
Southern California (1229)
Tennessee (72)
Texas (634)
United States (12534)
Utah (82)
Virginia (68)
Washington D.C. (34)
Washington State (345)
West Virginia (2)
Wisconsin (42)
337,487 Results for "memorial sloan kettering cancer center".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company’s Novel Oral Ketamine Analog
MIRA Pharmaceuticals, Inc. announced it is in advanced discussions with Memorial Sloan Kettering Cancer Center (MSK) to initiate a preclinical study evaluating MIRA’s novel oral ketamine analog, Ketamir-2, for the treatment of cancer-related pain and depression.
May 21, 2024
·
8 min read
Drug Development
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer
IMUNON, Inc. (NASDAQ: IMNN) announces that Memorial Sloan Kettering Cancer Center has joined MD Anderson Cancer Center in enrolling patients in a Phase 1/2 clinical trial evaluating IMUNON’s IMNN-001 in combination with bevacizumab in patients with advanced ovarian cancer.
February 27, 2024
·
6 min read
Business
Nexcella Announces Dr. Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board
Dr. Landau joins the Nexcella Scientific Advisory Board with decades of hematology/oncology clinical trial experience at Memorial Sloan Kettering Cancer Center.
August 18, 2023
·
5 min read
Business
Immix Biopharma Announces Dr. Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board
Dr. Landau joins the Nexcella Scientific Advisory Board with decades of hematology/oncology clinical trial experience at Memorial Sloan Kettering Cancer Center.
August 18, 2023
·
6 min read
Press Releases
Microbot Medical Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center
July 18, 2024
·
3 min read
BioCapital
The FNIH Awards 2023 Trailblazer Prize for Clinician-Scientists to Vinod Balachandran, M.D., from Memorial Sloan Kettering Cancer Center for Pancreatic Cancer Research
The Foundation for the National Institutes of Health has awarded its sixth annual Trailblazer Prize for Clinician-Scientists to Vinod Balachandran, M.D., at Memorial Sloan Kettering Cancer Center, for his groundbreaking research on immunotherapies for pancreatic cancer.
August 24, 2023
·
4 min read
BioMidwest
Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer Center
Biodesix, Inc. announced that it has entered into a new master collaborative research agreement with Memorial Sloan Kettering Cancer Center under which the teams will collaborate on a development plan for diagnostic tests aimed at improving the treatment of cancer.
March 25, 2024
·
4 min read
Pharm Country
Astrin Biosciences and Leading New York Cancer Center Announce New Cancer Research Collaboration
In a significant advancement for cancer research and treatment, Astrin Biosciences, a leader in AI-empowered 3D holographic technology for cancer cell detection, has announced a comprehensive research collaboration with Memorial Sloan Kettering Cancer Center.
January 24, 2024
·
1 min read
Biotech Beach
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”) today announced Memorial Sloan Kettering Cancer Center as lead clinical site for its NXC-201 relapsed/refractory AL Amyloidosis multi-site clinical trial.
March 20, 2024
·
4 min read
Business
Actinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering’s CAR-T Cell Therapy
Actinium Pharmaceuticals, Inc. announced the National Institutes of Health (NIH) awarded Actinium a Small Business Technology Transfer grant extension to support its clinical collaboration with Memorial Sloan Kettering Cancer Center (MSK) to study Iomab-ACT.
October 4, 2023
·
3 min read
1 of 33,749
Next
